We are live on ! Find out more
CPRX icon

Catalyst Pharmaceutical

Delisted

CPRX was delisted on the 14th of July, 2026.

387 hedge funds and large institutions have $2.59B invested in Catalyst Pharmaceutical in 2026 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 147 increasing their positions, 120 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more capital inflows, than outflows

Capital inflows: $481M | Capital outflows: $254M

39% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 41

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

23% more repeat investments, than reductions

Existing positions increased: 147 | Existing positions reduced: 120

2% more funds holding

Funds holding: 380 → 387 (+7)

1.1% more ownership

Funds ownership: 84.58% → 85.68% (+1.1%)

31% less call options, than puts

Call options by funds: $3.38M | Put options by funds: $4.88M

Holders
387
Holders Change
+7
Holders Change %
+1.84%
% of All Funds
4.7%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
57
Increased
147
Reduced
120
Closed
41
Calls
$3.38M
Puts
$4.88M
Net Calls
-$1.5M
Net Calls Change
-$1.33M

CPRX Hedge Fund Activity: Q1 2026 in Review

387 of the 8,237 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2026, worth a combined $2.59B — up 6.8% from $2.42B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new CPRX positions and 41 closed out — a net gain of 16 holders — while 147 added to existing stakes and 120 trimmed.

The largest buyer was American Century Companies, adding an estimated $26.5M. The largest seller was Fundsmith LLP, cutting an estimated $60M.

  • 387 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2026, up from 380 in Q4 2025.
  • Funds reported $2.59B of Catalyst Pharmaceutical stock for Q1 2026, up 6.8% quarter-over-quarter.
  • 57 funds opened new Catalyst Pharmaceutical positions in Q1 2026 and 41 closed out, a net change of +16 holders.
  • The largest Catalyst Pharmaceutical buyer in Q1 2026 was American Century Companies, an estimated $26.5M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2026 was Fundsmith LLP, an estimated $60M sold.

Based on aggregated 13F filings for Q1 2026.